AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01206075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
Study NCT01206075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
Study NCT00094575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Repair
Description: Endovascular Repair
Study NCT00094575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Open Repair
Description: Standard Open Repair
Study NCT02994017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiopulmonary exercise testing
Description: The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
Study NCT03072953 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APD334
Description: APD334 active treatment
Study NCT03001154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face Virtual Reality Exposure Therapy
Description: In session, systematic, hierarchical exposure to feared stimuli with therapist.
Study NCT03399968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
Study NCT03399968 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ESWT
Description: the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
Study NCT05110534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: additional oral hygiene appointments
Description: Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
Study NCT03830736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 1
Description: Oat based beverage with added different concentration of extracted oat component.
Study NCT03830736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 2
Description: Oat based beverage with added different concentration of extracted oat component.
Study NCT03830736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 3
Description: Oat based beverage with added different concentration of extracted oat component.
Study NCT03830736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 4
Description: Oat based beverage with added different concentration of extracted oat component.
Study NCT03830736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Glucose based beverage without added test components is used as control product
Study NCT01117584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet
Study NCT01117584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT01117584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet
Study NCT01117584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: oral tablet
Study NCT03356444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
Study NCT03356444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment
Study NCT02576340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: otilonium bromide
Description: otilonium bromide was administered before the procedure
Study NCT03870191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of either twin block or trigger point injection.
Description: Study participants will be randomized into either group and will receive the intervention.
Study NCT01927952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kirschner wire
Description: Surgical fixation utiliziing Kirschner wire
Study NCT01927952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integra IPP-On PIP Fusion System
Description: surgical fixation utilizing the Integra IPP-On PIP Fusion System
Study NCT01927952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Smart-Toe Implant
Description: surgical fixation utilizing the Stryker Smart-Toe Implant
Study NCT04333329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROLITH
Description: transcranial pulse stimulation (TPS)
Study NCT02837497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU-RESUS CPR Improvement Bundle
Description: 1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings
Study NCT00562679 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Study NCT03001154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered Virtual Reality Exposure Therapy
Description: Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
Study NCT03001154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting-list
Description: Weekly assessments of public speaking
Study NCT05798689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic administration and gluten
Description: Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
Study NCT02707913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Amlodipine Tablet 10mg
Description: BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study NCT02707913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc Tablet 10mg
Description: Norvasc Tablet 10mg will be used as a comparator drug for the BE study
Study NCT02214693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Study NCT02095899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rufinamide
Description: 2x200mg up to max 2x800mg a day Titration over 20days
Study NCT02095899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: 2x200mg up to max 2x800mg a day Titration over 20days
Study NCT02163954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
Study NCT02163954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
Study NCT02163954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
Study NCT02163954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
Study NCT01685606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cellular immunotherapy
Description: A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
Study NCT04141943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)
Study NCT04645394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)
Study NCT02845050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy
Study NCT02845050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy
Study NCT02845050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
Study NCT02563613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Description: Core session: 2 hours, Booster session: 1 hour
Study NCT02563613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD)
Description: Core session: 2 hours, Booster session: 1 hour
Study NCT02563613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list Control (C)
Description: The wait-list control group will receive the intervention at 3 months.
Study NCT03419325 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 test
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
Study NCT05798689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration and gluten
Description: The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
Study NCT02562248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated screening for pediatric anxiety
Description: families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
Study NCT02562248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 10 mg PO q 6h scheduled
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg PO PRN
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 650 mg q 6h scheduled
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg q 6h scheduled
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg PO scheduled q6h
Study NCT06484439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: 5 mg hydrocodone PO PRN q6h
Study NCT00750555 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg per day orally until disease progression occurs, up to a maximum of 12 months
Study NCT02231450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 encapsulated film-coated tablets
Study NCT05078099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
Study NCT01260935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Hill Repair
Description: With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
Study NCT01260935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen Repair
Description: With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
Study NCT00730327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral modification
Description: Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
Study NCT01768819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
Study NCT00987831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B SLE one blood donation
Description: Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
Study NCT02807519 — intervention group
Intervention type: GENETIC
Intervention: collection of salivary cytokines
Description: Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
Study NCT00987831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawing only Group C
Description: Blood drawing and Brief medical history to ensure status of healthy control
Study NCT00987831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A SLE prospective study
Description: Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Chemotherapy)
Description: Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine (Chemotherapy)
Description: Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (Chemotherapy)
Description: Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
Study NCT01684878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan (Chemotherapy)
Description: Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
Study NCT00539708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation after extubation for 24 hours
Study NCT00539708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation after extubation for 24 hours
Study NCT02286973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT00284804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-060
Description: anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg